Professional
Added to YB: 2025-05-07
Pitch date: 2025-04-22
NVO [neutral]
Novo Nordisk A/S
-21.78%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 393.01
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
growth
Show full summary:
Polen Global Growth Portfolio Holding: Novo Nordisk A/S
NVO (holding update): Stock down 19% on disappointing CagriSema weight loss drug trial data in Q1, following similar December results. Despite concerns about next-gen drug's efficacy, still believe it has multi-billion dollar potential. Recent sell-off appears overdone.
Read full article (1 min)